RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (RAINBOW)
RAINBOW Study: a Randomized, Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, A-8036
- Novartis Investigative Site
-
Vienna, Austria, 1090
- Novartis Investigative Site
-
-
-
-
-
Brugge, Belgium, 8000
- Novartis Investigative Site
-
Gent, Belgium, 9000
- Novartis Investigative Site
-
-
-
-
-
Osijek, Croatia, 31000
- Novartis Investigative Site
-
Zagreb, Croatia, 10000
- Novartis Investigative Site
-
-
-
-
-
Praha, Czechia, 12808
- Novartis Investigative Site
-
-
Czech Republic
-
Ostrava Poruba, Czech Republic, Czechia, 708 52
- Novartis Investigative Site
-
Praha 4 - Podoli, Czech Republic, Czechia, 14700
- Novartis Investigative Site
-
-
-
-
-
Koebenhavn Ø, Denmark, 2100
- Novartis Investigative Site
-
-
-
-
-
Alexandria, Egypt, 21131
- Novartis Investigative Site
-
-
-
-
-
Tallinn, Estonia, 13419
- Novartis Investigative Site
-
-
-
-
-
Amiens Cedex 1, France, 80054
- Novartis Investigative Site
-
Marseille, France, 13915
- Novartis Investigative Site
-
-
-
-
-
Bonn, Germany, 53127
- Novartis Investigative Site
-
Hannover, Germany, 30625
- Novartis Investigative Site
-
-
-
-
-
Goudi- Athens, Greece, 115 27
- Novartis Investigative Site
-
-
GR
-
Ampelokipi, GR, Greece, 115 27
- Novartis Investigative Site
-
Thessaloniki, GR, Greece, 546 29
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary, 1125
- Novartis Investigative Site
-
Debrecen, Hungary, 4032
- Novartis Investigative Site
-
-
-
-
-
New Delhi, India, 110029
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380016
- Novartis Investigative Site
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400 008
- Novartis Investigative Site
-
-
Tamil Nadu
-
Coimbatore, Tamil Nadu, India, 641014
- Novartis Investigative Site
-
Madurai, Tamil Nadu, India, 625020
- Novartis Investigative Site
-
-
Thiruvanantapuram
-
Vanchiyoor, Thiruvanantapuram, India, 695035
- Novartis Investigative Site
-
-
-
-
FI
-
Firenze, FI, Italy, 50139
- Novartis Investigative Site
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Novartis Investigative Site
-
-
PG
-
Perugia, PG, Italy, 06100
- Novartis Investigative Site
-
-
RM
-
Fiumicino, RM, Italy, 00054
- Novartis Investigative Site
-
-
-
-
Aichi
-
Nagoya, Aichi, Japan, 453-8511
- Novartis Investigative Site
-
Nagoya, Aichi, Japan, 466 8560
- Novartis Investigative Site
-
-
Chiba
-
Yachiyo-city, Chiba, Japan, 276-8524
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka city, Fukuoka, Japan, 812-8582
- Novartis Investigative Site
-
Fukuoka-city, Fukuoka, Japan, 814-0180
- Novartis Investigative Site
-
Kurume city, Fukuoka, Japan, 830-0011
- Novartis Investigative Site
-
-
Fukushima
-
Fukushima-city, Fukushima, Japan, 960-1295
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo-city, Hokkaido, Japan
- Novartis Investigative Site
-
-
Kagawa
-
Zentsuji-city, Kagawa, Japan, 765-8507
- Novartis Investigative Site
-
-
Okinawa
-
Shimajiri-Gun, Okinawa, Japan, 901-1303
- Novartis Investigative Site
-
-
Osaka
-
Izumi-city, Osaka, Japan, 594-1101
- Novartis Investigative Site
-
-
Shiga
-
Ohtsu-city, Shiga, Japan, 520-2192
- Novartis Investigative Site
-
-
Tokyo
-
Fuchu-city, Tokyo, Japan, 183-8561
- Novartis Investigative Site
-
Ota-ku, Tokyo, Japan, 143 8541
- Novartis Investigative Site
-
Setagaya-ku, Tokyo, Japan, 157-8535
- Novartis Investigative Site
-
Sumida-ku, Tokyo, Japan, 130-8575
- Novartis Investigative Site
-
Toshima-ku, Tokyo, Japan, 170-8476
- Novartis Investigative Site
-
-
-
-
LTU
-
Kaunas, LTU, Lithuania, LT-50161
- Novartis Investigative Site
-
-
-
-
Sabah
-
Kota Kinabalu, Sabah, Malaysia, 88996
- Novartis Investigative Site
-
-
Wilayah Persekutuan
-
Kuala Lumpur, Wilayah Persekutuan, Malaysia, 50586
- Novartis Investigative Site
-
-
-
-
-
Querataro, Mexico, 76090
- Novartis Investigative Site
-
-
-
-
-
Bialystok, Poland, 15-274
- Novartis Investigative Site
-
Wroclaw, Poland, 51-124
- Novartis Investigative Site
-
-
-
-
-
Brasov, Romania, 500025
- Novartis Investigative Site
-
Bucuresti, Romania, 020395
- Novartis Investigative Site
-
Timisoara, Romania, 300041
- Novartis Investigative Site
-
-
-
-
-
Cheboksary, Russian Federation, 428028
- Novartis Investigative Site
-
Kazan, Russian Federation, 420012
- Novartis Investigative Site
-
Moscow, Russian Federation, 127486
- Novartis Investigative Site
-
Saint-Petersburg, Russian Federation, 194100
- Novartis Investigative Site
-
-
-
-
-
Riyadh, Saudi Arabia, 11211
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovakia, 833 40
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
Taoyuan, Taiwan, 33305
- Novartis Investigative Site
-
-
-
-
-
Ankara, Turkey, 06100
- Novartis Investigative Site
-
Ankara, Turkey, 06500
- Novartis Investigative Site
-
Istanbul, Turkey, 34140
- Novartis Investigative Site
-
Soguksu / Antalya, Turkey, 07100
- Novartis Investigative Site
-
Zuhuratbaba / Istanbul, Turkey, 34147
- Novartis Investigative Site
-
-
Meselik
-
Eskisehir, Meselik, Turkey, 26480
- Novartis Investigative Site
-
-
-
-
-
Manchester, United Kingdom, M13 9WL
- Novartis Investigative Site
-
Oxford, United Kingdom, OX3 9DU
- Novartis Investigative Site
-
Portsmouth, United Kingdom, PO6 3LY
- Novartis Investigative Site
-
-
-
-
California
-
Loma Linda, California, United States, 92354
- Novartis Investigative Site
-
Sacramento, California, United States, 95817
- Novartis Investigative Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Novartis Investigative Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Novartis Investigative Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40208
- Novartis Investigative Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Novartis Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Novartis Investigative Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Novartis Investigative Site
-
-
New York
-
Rochester, New York, United States, 14642
- Novartis Investigative Site
-
-
Texas
-
Austin, Texas, United States, 78705
- Novartis Investigative Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Novartis Investigative Site
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- preterm infants with a birth weight of less than 1500 g
- bilateral ROP with one of the following retinal findings in each eye: Zone I, stage 1+, 2+, 3 or 3+ disease, or Zone II, stage 3+ disease, or Aggressive posterior retinopathy of prematurity (AP-ROP)
Exclusion Criteria:
- ROP disease characteristic in either eye other than that listed above at the time of the first investigational treatment
- A history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes
- Had received any previous surgical or nonsurgical treatment for ROP (e.g., ablative laser therapy or cryotherapy, vitrectomy)
- Had been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)
- Had used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever was longer
- Had ocular structural abnormalities that were assessed by the Investigator to have had a clinically significant impact on study assessments
- Had active ocular infection within 5 days before or on the day of first investigational treatment
- Had a history of hydrocephalus requiring treatment
- Had a history of any other neurological conditions that are assessed by the Investigator to have a significant risk of severe impact on visual function
- Had any other medical conditions or clinically significant comorbidities or personal circumstances that were assessed by the Investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments (e.g., poor life expectancy, pupil not able to be adequately dilated, unable to comply with the visit schedule)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ranibizumab 0.2 mg
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
|
Administered as an intravitreal injection
|
|
Experimental: Ranibizumab 0.1 mg
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
|
Administered as an intravitreal injection
|
|
Active Comparator: Laser therapy
Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
|
Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24
Time Frame: Week 24
|
To achieve this outcome, patients must fulfill all the following criteria, 1) survival, 2) no intervention with a second modality for ROP, 3) absence of active ROP and 4) absence of unfavorable structural outcome.
Retinopathy of prematurity (ROP) is a pathologic process that occurs in the incompletely vascularized, developing retina of low birth-weight preterm neonates.
|
Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Requiring Interventions With a Second Modality for ROP at Week 24
Time Frame: Week 24
|
Intervention for ROP in either eye at or before the 24-week assessment visit with a treatment modality other than the modality of the first study treatment.
Only descriptive analysis done.
|
Week 24
|
|
Number of Participants Experiencing an Event, From the First Study Treatment to the Last Study Visit
Time Frame: Day 1 (after initiation of study treatment) up to study exit (Day 169)
|
An event was defined as death, treatment switch, or the first occurrence of unfavorable structural outcomes in either eye.
Only descriptive analysis done.
|
Day 1 (after initiation of study treatment) up to study exit (Day 169)
|
|
Percentage of Participants Having Recurrent ROP and Receiving Any Post-baseline Intervention at or Before Week 24
Time Frame: Week 24
|
Recurrence of ROP is defined as subjects receiving any post-baseline intervention in either eye at or before 24 weeks (ranibizumab re-treatment or switch to laser in the ranibizumab groups, switch to ranibizumab treatment in the laser group).
Zone I consists of a circle, the radius of which extends from the center of the optic disc to twice the distance from the center of the optic disc to the center of the macula.
Zone II extends centrifugally from the edge of zone I to the nasal ora serrata.
Only descriptive analysis done.
|
Week 24
|
|
Percent of Participants With Ocular Adverse Events by Primary System Organ (SOCs) at Week 24
Time Frame: Week 24
|
Percent of Participants with Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment.
Only descriptive analysis done.
|
Week 24
|
|
Mean Change in Ranibizumab Concentration in Pharmacokinetic Serum Samples Over Time at Day 1, Day 15 and Day 29
Time Frame: Day 1 (Baseline), Day 15 and Day 29
|
Blood samples for the determination of ranibizumab concentrations were collected in the Ranibizumab treatment arms only at the following time points: within 24 hours after the first administration of ranibizumab, at Day 15 and at Day 29.
Only descriptive analysis done.
|
Day 1 (Baseline), Day 15 and Day 29
|
|
Mean Change in Vascular Endothelial Growth Factor (VEGF) Levels Over Time at Day 1, Day 15 and Day 29
Time Frame: Day 1 (Baseline), Day 15 and Day 29
|
Blood samples for the determination of systemic VEGF levels were collected at the following time points: before the first investigational treatment, at Day 15 and at Day 29.
Only descriptive analysis done.
|
Day 1 (Baseline), Day 15 and Day 29
|
|
Total Number of Ranibizumab Injections Received at Week 24
Time Frame: Week 24
|
Patients randomized to receive Ranibizumab 0.1 mg or 0.2 mg received a single dose of intravitreal Ranibizumab to each eye on Day 1 (Baseline).
Only descriptive analysis done.
|
Week 24
|
|
Percent of Participants With Non-Ocular Adverse Events by Primary System Organ (SOCs) at Week 24
Time Frame: Week 24
|
Percent of Participants with Non-Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment.
Only descriptive analysis done.
|
Week 24
|
|
Mean Change From Baseline in Vital Signs (Body Length, Head Circumference and Knee to Heel Length) at Day 85 and Day 169
Time Frame: Baseline, Day 85, Day 169
|
Body Length, Head Circumference and Knee to Heel Length were assessed.
Only descriptive analysis done.
|
Baseline, Day 85, Day 169
|
|
Mean Change From Baseline in Vital Signs (Weight) at Day 85 and Day 169
Time Frame: Baseline, Day 85, Day 169
|
Body weight was measured.
Only descriptive analysis done.
|
Baseline, Day 85, Day 169
|
|
Mean Change From Baseline in Vital Signs (Sitting Blood Pressure) at Day 85 and Day 169
Time Frame: Baseline, Day 85, Day 169
|
Blood Pressure measurements were not required by the protocol.
Instead, the most recent Systolic and Diastolic Blood Pressure expressed in millimeters of mercury (mmHg) measured as part of the routine clinical care were used.
Only descriptive analysis done.
|
Baseline, Day 85, Day 169
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Fleck BW, Reynolds JD, Zhu Q, Lepore D, Marlow N, Stahl A, Li J, Weisberger A, Fielder AR; RAINBOW Investigator Group. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial. Ophthalmol Retina. 2022 Jul;6(7):628-637. doi: 10.1016/j.oret.2022.02.006. Epub 2022 Feb 22.
- Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019 Oct 26;394(10208):1551-1559. doi: 10.1016/S0140-6736(19)31344-3. Epub 2019 Sep 12.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Infant, Newborn, Diseases
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Infant, Premature, Diseases
- Retinal Diseases
- Premature Birth
- Retinopathy of Prematurity
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
Other Study ID Numbers
- CRFB002H2301
- 2014-003041-10 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.